Otros idiomas FluoGuide A/S

Acciones

FLUO

DK0061123312

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:29:40 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
47,9 ^SEK	+2,13 %		-1,54 %	-21,73 %

30/05	FluoGuide A/S comunica los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
27/05	FluoGuide elige un sistema láser para el tratamiento de terapia fototérmica FG001	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05
FluoGuide Picks Laser System for FG001 Photothermal Therapy Treatment	27/05
Fluoguide Selects Laser System for Photothermal Cancer Therapy with Fg001	27/05
FluoGuide A/S Approves Board Changes	20/03
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	12/03
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001	08/01
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer	13/11
FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference	06/11
Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague	07/09/23
FluoGuide A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23
Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer	28/08/23
FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer	20/06/23
Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer	07/06/23
FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23
FluoGuide A/S Appoints Michael Thyrring Engsig as Member of the Board of Directors	21/03/23
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23
FluoGuide A/S Updates on Recruitment in Phase IIb Aggressive Brain Cancer Trial with FG001	27/02/23
Sweden's FluoGuide Names Successor as CFO Resigns	02/02/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas FluoGuide A/S

Acciones

FLUO

DK0061123312

Otros idiomas

Filtros